Indian equities extended their decline on Tuesday, with Nifty and Sensex hitting fresh six-month lows. Broader markets also weakened, while...

Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organo...

Anupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...

Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...

Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers al...

NSE slipped below their Rs 1,785 IPO price on Monday, taking its market capitalisation to Rs 4.36 lakh crore. Despite the decline, brokerag...

The Central Drugs Standard Control Organisation is addressing regulatory gaps related to the illegal diversion of pharmaceutical drugs. Fol...

Electronics manufacturing companies have received substantial incentives under the production-linked incentive scheme and attracted signifi...

Around 10 companies have set record dates for dividends and bonus issues between September 28 and October 1, making it a relatively quiet w...

Nifty ended at 23,140.50 after an eighth consecutive weekly decline, with technical indicators remaining bearish. Analysts identify 23,300 ...

HRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...

Jagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisit...

India's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...

"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...

Drugmakers for months have been warning they could curtail investments and delay the release of new medications in Europe, widening a dispa...

HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...